Moderna (English Wikipedia)

Tirrell M (May 12, 2015). "The biotech targeting personalized medicine". CNBC. Archived from the original on March 21, 2021. Retrieved June 5, 2023.

congress.gov (Global: 392^nd place; English: 262^nd place)

crsreports.congress.gov

Siddalingaiah SV (March 1, 2021). "Operation Warp Speed Contracts for COVID-19 Vaccines and Ancillary Vaccination Materials". Congressional Research Service, United States Government. Retrieved February 12, 2023.

doi.org (Global: 2^nd place; English: 2^nd place)

Park KS, Sun X, Aikins ME, Moon JJ (December 2020). "Non-viral COVID-19 vaccine delivery systems". Advanced Drug Delivery Reviews. 169: 137–51. doi:10.1016/j.addr.2020.12.008. PMC 7744276. PMID 33340620.
Servick K (March 25, 2020). "This mysterious $2 billion biotech is revealing the secrets behind its new drugs and vaccines (from the original, 1 February 2017)". Science. doi:10.1126/science.aal0686. S2CID 241466550.
Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, et al. (February 17, 2017). "Modified mRNA Vaccines Protect against Zika Virus Infection". Cell. 168 (6): 1114–1125.e10. doi:10.1016/j.cell.2017.02.017. ISSN 0092-8674. PMC 5388441. PMID 28222903.
"Precision medicine meets cancer vaccines". Nature Medicine. 29 (6): 1287. June 16, 2023. doi:10.1038/s41591-023-02432-2. PMID 37328586. S2CID 259184146.
Bafaloukos D (2023). "Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects". Vaccines. 11 (3): 636. doi:10.3390/vaccines11030636. PMC 10057252. PMID 36992220.
Ledford H (December 18, 2020). "Moderna COVID vaccine becomes second to get US authorization". Nature. doi:10.1038/d41586-020-03593-7. PMID 33340017. S2CID 243212854.

fda.gov (Global: 470^th place; English: 329^th place)

"FDA Roundup: May 31, 2024". U.S. Food and Drug Administration (FDA) (Press release). May 31, 2024. Archived from the original on May 31, 2024. Retrieved May 31, 2024. This article incorporates text from this source, which is in the public domain.
"Moderna COVID-19 vaccines". U.S. Food and Drug Administration (FDA). December 15, 2022. Retrieved February 11, 2023.

fiercepharma.com (Global: low place; English: 8,341^st place)

Kansteiner F (September 5, 2025). "Seeking royalties, GSK expands mRNA patent litigation to include Moderna's next-generation COVID shot". Fierce Pharma.

fortune.com (Global: 647^th place; English: 421^st place)

Mukherjee S (December 8, 2018). "Moderna Had the Biggest Biotech IPO Ever. Here's What That Says About the Industry's Future". Fortune. Archived from the original on November 16, 2020.

ft.com (Global: 193^rd place; English: 127^th place)

"Moderna shares nearly triple on skin cancer vaccine success". Financial Times. August 19, 2026. Archived from the original on August 20, 2026. Retrieved August 20, 2026.
Kuchler H, Mancini DP (July 5, 2023). "US biotech Moderna strikes deal to develop mRNA drugs in China". Financial Times.

ghostarchive.org (Global: 64^th place; English: 28^th place)

"Moderna shares nearly triple on skin cancer vaccine success". Financial Times. August 19, 2026. Archived from the original on August 20, 2026. Retrieved August 20, 2026.

modernatx.com (Global: low place; English: low place)

"Key Facts". Moderna.
"Moderna, Our story; Our big moments". Moderna, Inc. 2023. Retrieved February 10, 2023.
"Moderna: Strategic collaborators". Moderna, Inc. 2023. Retrieved February 11, 2023.

montrealgazette.com (Global: 1,967^th place; English: 980^th place)

"Moderna will supply COVID-19 vaccines made in Laval by fall 2025". The Gazette.

nih.gov (Global: 5^th place; English: 5^th place)

nytimes.com (Global: 7^th place; English: 7^th place)

Mueller B (February 23, 2023). "After Long Delay, Moderna Pays N.I.H. for Covid Vaccine Technique". The New York Times.
Robbins R, Gross J (August 26, 2022). "Moderna Sues Pfizer and BioNTech Over Covid Vaccine Technology". The New York Times. ISSN 0362-4331.

pharmanewsintel.com (Global: low place; English: low place)

Schmidt H (January 5, 2023). "Moderna to Buy Japanese Firm OriCiro in Its First-Ever Acquisition". PharmaNews Intelligence.

politifact.com (Global: 3,520^th place; English: 1,999^th place)

Valverde M (November 19, 2020). "How Pfizer's and Moderna's COVID-19 vaccines are tied to Operation Warp Speed". PolitiFact. Retrieved February 12, 2023.

prnewswire.com (Global: 546^th place; English: 310^th place)

"Moderna Launches Onkaido Therapeutics to Focus on the Development of mRNA Therapeutics™ in Oncology with $20 Million Capital Commitment" (Press release). PR Newswire. January 14, 2014. Archived from the original on November 20, 2016.
"Moderna Launches New Venture Valera LLC for Infectious Diseases" (Press release). PR Newswire. January 8, 2015. Archived from the original on November 19, 2016.
"Moderna Launches Third Venture Company Elpidera for Rare Diseases" (Press release). PR Newswire. May 12, 2015. Archived from the original on October 12, 2016.

reuters.com (Global: 38^th place; English: 30^th place)

"Moderna, Merck vaccine cuts recurrence and spread of melanoma, raising new treatment hope". Reuters (published August 20, 2026). August 19, 2026. Retrieved August 20, 2026.{{cite news}}: CS1 maint: url-status (link)
"Moderna shares fall after judge sides with Arbutus in patent fight". Reuters. April 3, 2024. Retrieved May 19, 2024.
Brittain B (April 11, 2023). "Moderna fends off Arbutus appeal in COVID-19 vaccine patent fight". Reuters.
Brittain B (October 16, 2024). "GSK sues Moderna for US patent infringement over COVID, RSV vaccines". Reuters. Retrieved November 8, 2024.

science.org (Global: 1,007^th place; English: 665^th place)

Servick K (March 25, 2020). "This mysterious $2 billion biotech is revealing the secrets behind its new drugs and vaccines (from the original, 1 February 2017)". Science. doi:10.1126/science.aal0686. S2CID 241466550.

scientificamerican.com (Global: 1,110^th place; English: 817^th place)

"'Landmark' trial shows mRNA therapy significantly cuts the odds of recurrent skin cancer". Scientific American. August 19, 2026. Archived from the original on August 20, 2026. Retrieved August 23, 2026.

sec.gov (Global: 617^th place; English: 437^th place)

"2025 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 20, 2026.
"Moderna, Inc. Schedule 14A 2022 Proxy Statement". U.S. Securities and Exchange Commission. March 9, 2022.
"Moderna, Inc., 2024, Form 10-K Annual Report". U.S. Securities and Exchange Commission. February 21, 2025.

semanticscholar.org (Global: 15^th place; English: 8^th place)

api.semanticscholar.org

Servick K (March 25, 2020). "This mysterious $2 billion biotech is revealing the secrets behind its new drugs and vaccines (from the original, 1 February 2017)". Science. doi:10.1126/science.aal0686. S2CID 241466550.
"Precision medicine meets cancer vaccines". Nature Medicine. 29 (6): 1287. June 16, 2023. doi:10.1038/s41591-023-02432-2. PMID 37328586. S2CID 259184146.
Ledford H (December 18, 2020). "Moderna COVID vaccine becomes second to get US authorization". Nature. doi:10.1038/d41586-020-03593-7. PMID 33340017. S2CID 243212854.

statnews.com (Global: 7,413^th place; English: 4,542^nd place)

Garde D, Saltzman J (November 10, 2020). "The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race". Stat. Archived from the original on November 10, 2020.
Garde D (September 13, 2016). "Ego, ambition, and turmoil: Inside one of biotech's most secretive startups". Stat. Archived from the original on November 16, 2020.
Garde D (July 27, 2017). "Key partner cuts ties with brash biotech startup Moderna, raising big questions about its pipeline". Stat.

time.com (Global: 84^th place; English: 63^rd place)

Hu C. "The World's Most Impactful Companies of 2026". Time. Archived from the original on July 25, 2026. Retrieved August 12, 2026.

web.archive.org (Global: 1^st place; English: 1^st place)

Garde D, Saltzman J (November 10, 2020). "The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race". Stat. Archived from the original on November 10, 2020.
Hu C. "The World's Most Impactful Companies of 2026". Time. Archived from the original on July 25, 2026. Retrieved August 12, 2026.
Elton C (March 2013). "The NEXT Next Big Thing". Boston Magazine. Archived from the original on November 16, 2020.
Garde D (September 13, 2016). "Ego, ambition, and turmoil: Inside one of biotech's most secretive startups". Stat. Archived from the original on November 16, 2020.
Reidy C (January 13, 2014). "Alexion, Moderna announce agreement to develop messenger RNA therapeutics". Boston Globe Media Partners. Archived from the original on June 24, 2021. Retrieved June 5, 2023.
"Moderna Launches Onkaido Therapeutics to Focus on the Development of mRNA Therapeutics™ in Oncology with $20 Million Capital Commitment" (Press release). PR Newswire. January 14, 2014. Archived from the original on November 20, 2016.
Gormley B (January 15, 2014). "Moderna Launches Cancer Drug Co. Onkaido Therapeutics With $20M Investment". The Wall Street Journal. ISSN 0099-9660. Archived from the original on June 5, 2023. Retrieved June 5, 2023.
"Moderna Launches New Venture Valera LLC for Infectious Diseases" (Press release). PR Newswire. January 8, 2015. Archived from the original on November 19, 2016.
"Moderna Launches New Venture Valera LLC for Infectious Diseases". Bionity. January 12, 2015. Archived from the original on June 5, 2023. Retrieved June 5, 2023.
"Moderna Launches Third Venture Company Elpidera for Rare Diseases" (Press release). PR Newswire. May 12, 2015. Archived from the original on October 12, 2016.
Tirrell M (May 12, 2015). "The biotech targeting personalized medicine". CNBC. Archived from the original on March 21, 2021. Retrieved June 5, 2023.
Weisman R (March 21, 2013). "Moderna in line for $240m licensing deal". The Boston Globe. Archived from the original on November 16, 2020.
Mukherjee S (December 8, 2018). "Moderna Had the Biggest Biotech IPO Ever. Here's What That Says About the Industry's Future". Fortune. Archived from the original on November 16, 2020.
Ramsey L (December 7, 2018). "Moderna just priced the biggest IPO in biotech history, valuing the startup at $7.5 billion". Business Insider. Archived from the original on November 16, 2020.
"'Landmark' trial shows mRNA therapy significantly cuts the odds of recurrent skin cancer". Scientific American. August 19, 2026. Archived from the original on August 20, 2026. Retrieved August 23, 2026.
"FDA Roundup: May 31, 2024". U.S. Food and Drug Administration (FDA) (Press release). May 31, 2024. Archived from the original on May 31, 2024. Retrieved May 31, 2024. This article incorporates text from this source, which is in the public domain.

worldcat.org (Global: 4^th place; English: 4^th place)

search.worldcat.org

Gormley B (January 15, 2014). "Moderna Launches Cancer Drug Co. Onkaido Therapeutics With $20M Investment". The Wall Street Journal. ISSN 0099-9660. Archived from the original on June 5, 2023. Retrieved June 5, 2023.
Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, et al. (February 17, 2017). "Modified mRNA Vaccines Protect against Zika Virus Infection". Cell. 168 (6): 1114–1125.e10. doi:10.1016/j.cell.2017.02.017. ISSN 0092-8674. PMC 5388441. PMID 28222903.
Robbins R, Gross J (August 26, 2022). "Moderna Sues Pfizer and BioNTech Over Covid Vaccine Technology". The New York Times. ISSN 0362-4331.

wsj.com (Global: 94^th place; English: 66^th place)

Gormley B (January 15, 2014). "Moderna Launches Cancer Drug Co. Onkaido Therapeutics With $20M Investment". The Wall Street Journal. ISSN 0099-9660. Archived from the original on June 5, 2023. Retrieved June 5, 2023.

youtube.com (Global: 13^th place; English: 14^th place)

Moderna (October 23, 2019). mRNA-3704 and Methylmalonic Acidemia (video) – via YouTube.

Moderna (English Wikipedia)

accesswire.com (Global: low place; English: low place)

ap.org (Global: 1,968th place; English: 1,138th place)

apnews.com (Global: 101st place; English: 62nd place)

bionity.com (Global: low place; English: low place)

biospace.com (Global: low place; English: 6,244th place)

bizjournals.com (Global: 396th place; English: 190th place)

bloomberg.com (Global: 118th place; English: 85th place)

boston.com (Global: 468th place; English: 271st place)

bostonglobe.com (Global: 657th place; English: 344th place)

bostonmagazine.com (Global: 4,816th place; English: 2,494th place)

businessinsider.com (Global: 201st place; English: 139th place)

cbc.ca (Global: 110th place; English: 65th place)

cnbc.com (Global: 303rd place; English: 191st place)

congress.gov (Global: 392nd place; English: 262nd place)

crsreports.congress.gov

doi.org (Global: 2nd place; English: 2nd place)

fda.gov (Global: 470th place; English: 329th place)

fiercepharma.com (Global: low place; English: 8,341st place)

fortune.com (Global: 647th place; English: 421st place)

ft.com (Global: 193rd place; English: 127th place)

ghostarchive.org (Global: 64th place; English: 28th place)

modernatx.com (Global: low place; English: low place)

montrealgazette.com (Global: 1,967th place; English: 980th place)

nih.gov (Global: 5th place; English: 5th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

nih.gov

nytimes.com (Global: 7th place; English: 7th place)

pharmanewsintel.com (Global: low place; English: low place)

politifact.com (Global: 3,520th place; English: 1,999th place)

prnewswire.com (Global: 546th place; English: 310th place)

reuters.com (Global: 38th place; English: 30th place)

science.org (Global: 1,007th place; English: 665th place)

scientificamerican.com (Global: 1,110th place; English: 817th place)

sec.gov (Global: 617th place; English: 437th place)

semanticscholar.org (Global: 15th place; English: 8th place)

api.semanticscholar.org

statnews.com (Global: 7,413th place; English: 4,542nd place)

time.com (Global: 84th place; English: 63rd place)

web.archive.org (Global: 1st place; English: 1st place)

worldcat.org (Global: 4th place; English: 4th place)

search.worldcat.org

wsj.com (Global: 94th place; English: 66th place)

youtube.com (Global: 13th place; English: 14th place)

ap.org (Global: 1,968^th place; English: 1,138^th place)

apnews.com (Global: 101^st place; English: 62^nd place)

biospace.com (Global: low place; English: 6,244^th place)

bizjournals.com (Global: 396^th place; English: 190^th place)

bloomberg.com (Global: 118^th place; English: 85^th place)

boston.com (Global: 468^th place; English: 271^st place)

bostonglobe.com (Global: 657^th place; English: 344^th place)

bostonmagazine.com (Global: 4,816^th place; English: 2,494^th place)

businessinsider.com (Global: 201^st place; English: 139^th place)

cbc.ca (Global: 110^th place; English: 65^th place)

cnbc.com (Global: 303^rd place; English: 191^st place)

congress.gov (Global: 392^nd place; English: 262^nd place)

doi.org (Global: 2^nd place; English: 2^nd place)

fda.gov (Global: 470^th place; English: 329^th place)

fiercepharma.com (Global: low place; English: 8,341^st place)

fortune.com (Global: 647^th place; English: 421^st place)

ft.com (Global: 193^rd place; English: 127^th place)

ghostarchive.org (Global: 64^th place; English: 28^th place)

montrealgazette.com (Global: 1,967^th place; English: 980^th place)

nih.gov (Global: 5^th place; English: 5^th place)

nytimes.com (Global: 7^th place; English: 7^th place)

politifact.com (Global: 3,520^th place; English: 1,999^th place)

prnewswire.com (Global: 546^th place; English: 310^th place)

reuters.com (Global: 38^th place; English: 30^th place)

science.org (Global: 1,007^th place; English: 665^th place)

scientificamerican.com (Global: 1,110^th place; English: 817^th place)

sec.gov (Global: 617^th place; English: 437^th place)

semanticscholar.org (Global: 15^th place; English: 8^th place)

statnews.com (Global: 7,413^th place; English: 4,542^nd place)

time.com (Global: 84^th place; English: 63^rd place)

web.archive.org (Global: 1^st place; English: 1^st place)

worldcat.org (Global: 4^th place; English: 4^th place)

wsj.com (Global: 94^th place; English: 66^th place)

youtube.com (Global: 13^th place; English: 14^th place)